<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192633</url>
  </required_header>
  <id_info>
    <org_study_id>GVP-SAR</org_study_id>
    <nct_id>NCT01192633</nct_id>
  </id_info>
  <brief_title>Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma</brief_title>
  <acronym>GVPS</acronym>
  <official_title>Phase Ⅱ Study of Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate PFS of gemcitabine,vincristine and
      cisplatin as second line therapy in patients with sarcoma. 40 patients will be treated into
      this study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival(Progression-free survival was evaluated for the period from the date of first treatment with this regimen to the date when disease progression was first observed or death occurred.)</measure>
    <time_frame>every 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>every 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects</measure>
    <time_frame>every 3 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Sarcoma</condition>
  <condition>Chemotherapy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GVP</intervention_name>
    <description>Drug: gemcitabine, vincristine,cisplatin
cisplatin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 vincristine 1.4mg/m2(less than 2 mg), iv, D1 repeat every 3 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Give written informed consent prior to study, with understanding that the patient has
             the right to withdraw from the study at any time without prejudice

          -  Be female of male and ≥18 and ≤75 years of age

          -  Be ambulatory and have ECOG performance status of ≤1

          -  Have histological confirmed sarcoma

          -  Locally advanced or metastatic sarcoma who receive first-line chemotherapy.

          -  Have at least one target lesion according to the RECIST criteria.

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  patient has received chemotherapy drugs including gemcitabine,vincristine and
             cisplatin

          -  Chemotherapy within four weeks preceding treatment start

          -  ECOG ≥ 2

          -  Radiotherapy to the axial skeleton within the 4 weeks preceding study treatment start
             or insufficient recovery from the effects of prior radiotherapy

          -  Participation in any investigational drug study within 4 weeks preceding treatment
             start

          -  History of another malignancy within the last five years except cured basal cell
             carcinoma of skin and carcinoma in-situ of uterine cervix .Abnormal laboratory values:
             hemoglobin &lt; 8. 0g/dl, neutrophil&lt; 1.5×109/L, platelet&lt; 100×109/L.

          -  serum creatine &gt; upper limit of normal (ULN)

          -  serum bilirubin &gt; ULN

          -  alanine aminotransferase(ALT) and aspartate aminotransferase(AST)&gt;5×ULN

          -  alkaline phosphatase(AKP)&gt;5×ULN

          -  Serious uncontrolled intercurrence infection

          -  Life expectancy of less than 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaonan Hong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhiguo Luo, PhD</last_name>
    <phone>862164175590</phone>
    <phone_ext>8908</phone_ext>
    <email>luozhiguo88@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiguo Luo, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Zhiyu Chen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001 Aug 1;19(15):3483-9.</citation>
    <PMID>11481354</PMID>
  </results_reference>
  <results_reference>
    <citation>Hartmann JT, Oechsle K, Huober J, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs. 2006 May;24(3):249-53.</citation>
    <PMID>16133789</PMID>
  </results_reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2010</study_first_submitted>
  <study_first_submitted_qc>August 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <last_update_submitted>August 31, 2010</last_update_submitted>
  <last_update_submitted_qc>August 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Base for drug clinical trials, Fudan University cancer hospital</name_title>
    <organization>Fudan University cancer hospital</organization>
  </responsible_party>
  <keyword>Sarcoma</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>vincristine</keyword>
  <keyword>cisplatin</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

